TSE:AKU - Akumin Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started C$4.75 0.00 (0.00 %) (As of 05/24/2019 04:00 PM ET)Previous CloseC$4.75Today's RangeC$4.75 - C$4.7552-Week RangeC$3.98 - C$7.05VolumeN/AAverage Volume5,295 shsMarket CapitalizationC$297.24 millionP/E Ratio51.63Dividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Akumin Inc. provides outpatient diagnostic imaging services in the United States. As of December 31, 2017, the company operated 74 imaging centers located in Florida, Pennsylvania, Delaware, Texas, Illinois, and Kansas. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders, and reduce unnecessary invasive procedures. The company provides a range of medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, radiology, arthrography, and other diagnostic or interventional radiology procedures; and medical billing services. Akumin Inc. is headquartered in Toronto, Canada. Receive AKU News and Ratings via Email Sign-up to receive the latest news and ratings for AKU and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolTSE:AKU Previous Symbol CUSIPN/A CIKN/A Webhttp://www.akumin.com/ Phone416-613-1391Debt Debt-to-Equity Ratio110.43 Current Ratio2.44 Quick Ratio2.39Price-To-Earnings Trailing P/E Ratio51.63 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$168.91 million Price / Sales1.76 Cash FlowC$0.32 per share Price / Cash Flow14.72 Book ValueC$1.67 per share Price / Book2.85Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares62,577,000Market CapC$297.24 million Next Earnings Date8/12/2019 (Estimated) OptionableNot Optionable Akumin (TSE:AKU) Frequently Asked Questions What is Akumin's stock symbol? Akumin trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AKU." How were Akumin's earnings last quarter? Akumin Inc (TSE:AKU) issued its earnings results on Friday, March, 29th. The company reported $0.07 earnings per share for the quarter, meeting analysts' consensus estimates of $0.07. The business earned $60.08 million during the quarter, compared to analyst estimates of $58.38 million. View Akumin's Earnings History. When is Akumin's next earnings date? Akumin is scheduled to release their next quarterly earnings announcement on Monday, August 12th 2019. View Earnings Estimates for Akumin. Has Akumin been receiving favorable news coverage? News headlines about AKU stock have trended positive recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Akumin earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. Who are some of Akumin's key competitors? Some companies that are related to Akumin include Integral Diagnostics (IDX), Senseonics (SENS), Senseonics (SENS), Palatin Technologies (PTN), Renalytix Ai (RENX), Profound Medical (PRN), MaxCyte (MXCT), Yourgene Health (YGEN), Oncimmune (ONC), Lexagene (LXG), Oncosil Medical (OSL), Sernova (SVA), SQI Diagnostics (SQD), Deepmatter Group (DMTR) and GeneNews (GEN). What other stocks do shareholders of Akumin own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akumin investors own include Brookfield Asset Management (BAM.A), Alimentation Couche-Tard (ATD.B), Algonquin Power & Utilities (AQN), Altagas (ALA), TENCENT HOLDING/ADR (TCEHY), NINTENDO LTD/ADR (NTDOY), Exxon Mobil (XOM), Mitsubishi UFJ Financial Group (MUFG), AutoZone (AZO) and GRUPO AVAL ACCI/S (AVAL). Who are Akumin's key executives? Akumin's management team includes the folowing people: Mr. Riadh Zine-El-Abidine, Pres, CEO & Director (Age 47)Mr. Mohammad Saleem, CFO & Corp. Sec.Mr. Rohit Navani, Exec. VP & COOMrs. Amy Adams MBA, Sr. VP of Clinical Devel.Ms. Laura Kassa, Sr. VP of Operations of Akumin Corp. How do I buy shares of Akumin? Shares of AKU and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Akumin's stock price today? One share of AKU stock can currently be purchased for approximately C$4.75. How big of a company is Akumin? Akumin has a market capitalization of C$297.24 million and generates C$168.91 million in revenue each year. What is Akumin's official website? The official website for Akumin is http://www.akumin.com/. How can I contact Akumin? The company can be reached via phone at 416-613-1391. MarketBeat Community Rating for Akumin (TSE AKU)Community Ranking: 1.7 out of 5 ()Outperform Votes: 5 (Vote Outperform)Underperform Votes: 10 (Vote Underperform)Total Votes: 15MarketBeat's community ratings are surveys of what our community members think about Akumin and other stocks. Vote "Outperform" if you believe AKU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKU will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: How is an ETF different from a mutual fund? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.